Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 1st-3rd, 2022-Naples, Italy)

By sjmartinez • July 29, 2023

Ascierto PA, Agarwala SS, Warner AB, Ernstoff MS, Fox BA, Gajewski TF, Galon J, Garbe C, Gastman BR, Gershenwald JE, Kalinski P, Krogsgaard M, Leidner RS, Lo RS, Menzies AM, Michielin O, Poulikakos PI, Weber JS, Caracò C, Osman I, Puzanov I, Thurin M. Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 1st-3rd, 2022-Naples, Italy). J Transl Med. 2023 Jul 28;21(1):508. doi: 10.1186/s12967-023-04325-x. PMID: 37507765; PMCID: PMC10375730.

Tags: Adjuvant, Anti-CTLA-4, Anti-PD-1, biomarkers, BRAF inhibitor, Combination strategies, Dermatology, immunotherapy, MEK inhibitor, melanoma, neoadjuvant, Publications, Target therapy

Inhibition of pyruvate oxidation diminishes melanoma progression

Seyran B, Avila I, Galvan C, Robles G, Murphy C, Christofk H, Lowry WE. Inhibition of pyruvate oxidation diminishes melanoma progression. J Invest Dermatol. 2024[...]

Low-Dose Oral Minoxidil Initiation for Patients With Hair Loss: An International Modified Delphi Consensus Statement

Akiska YM, Mirmirani P, Roseborough I, Mathes E, Bhutani T, Ambrosy A, Aguh C, Bergfeld W, Callender VD, Castelo-Soccio L, Cotsarelis G, Craiglow BG, Desai[...]

Mart-1 During Mohs Micrographic Surgery for Melanoma Excision Results in Decreased Stage Number and Decreased Frequency of Secondary Pathologic Consultation

Zhang R, Yueh K, Anderson M, Bennett RG. Mart-1 During Mohs Micrographic Surgery for Melanoma Excision Results in Decreased Stage Number and Decreased Frequency of[...]